CEO of TapImmune says technology has multiple opportunities to succeed Print E-mail
By Staff and Wire Reports   
Tuesday, 12 April 2011 06:05

Dr. Glynn Wilson, Chairman & CEO of TapImmune Inc. spoke to The Wall Street reporter on Monday.



Young biotech expected to move into human studies with vaccine for breast cancer

Tap Immune Inc (OTCBB:TPIV) CEO Interview

TapImmune Receives Notice of Allowance for U.S. Patent Application Relating to Vaccines Containing TAP for the Treatment of Pox Virus Infections

Since we alerted on the company, shares have continued to see more volume and increases, but despite the growing excitement on Wall Street and in various publications, many investors are not yet as familiar with the company and what is driving the market.

"The vaccine sector as a whole is the fastest growing sector of the pharmaceutical industry," explained Wilson. "Caner vaccines in particular have great potential. What we have done is we have a technology that is broadly applicable that works on its own or works in concert with synergistic technologies. That gives us multiple opportunities to parter, in addition to persuing our own pathway. I think we have have positioned ourselves to be a leader in this area with fundamentals together with our technology."

The complete interview, which investors should find very educational and informative as both a primer and update to the company's recent and upcoming developments, can be found here: http://www.wallstreetreporter.com/2011/04/tap-immune-inc-otcbbtpiv-ceo-interview/

 




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter